After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Pacira BioSciences Inc is $1.46B. A total of 0.53 million shares were traded on the day, compared to an average of 569.67K shares.
In the most recent transaction, PACE GARY W sold 90,000 shares of PCRX for 30.60 per share on Mar 08 ’24. After the transaction, the Director now owns 22,127 company shares. In a previous transaction on Mar 07 ’24, PACE GARY W sold 28,257 shares at 30.81 per share. PCRX shares that Director owns now total 112,127.
Among the insiders who sold shares, PACE GARY W disposed of 1,066 shares on Mar 06 ’24 at a per-share price of $29.67. This resulted in the Director holding 140,384 shares of PCRX after the transaction. In another insider transaction, WINSTON ROY sold 509 shares at $34.88 per share on Aug 02 ’23. Company shares held by the Chief Medical Officer now total 52,440.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, PCRX has a high of $48.60 and a low of $25.93.
As of this writing, PCRX has an earnings estimate of $0.65 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $0.88 per share and a lower estimate of $0.5. The company reported an EPS of $0.72 in the last quarter, which was -7.70% lower than expectations of $0.78.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $18.72, while its Total Shareholder’s Equity was $730.41M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Buy with a score of 4.70.
